Bioniq has raised $15.0M in total across 1 funding round.
Bioniq's investors include HV Capital, Norrsken VC, Picus Capital.
Bioniq is a UK-based health tech company launched in 2019 that builds AI-driven personalized supplements using blood test data and a proprietary biochemical database.[1][2][4] It serves individuals seeking optimized health—such as athletes, professionals, and wellness enthusiasts—by analyzing biomarkers like height, weight, age, lifestyle, and health goals to create tailor-made nutrient formulas addressing micronutrient deficiencies.[1][2][4] The core problem it solves is the inefficiency of one-size-fits-all supplements, delivering precise, evolving dosages via patented gradual-release granules for goals like better sleep, focus, and muscle mass.[1][4] With over 100,000 users across five continents, a $75M valuation post-$15M Series B in 2025, and high-profile backing from Cristiano Ronaldo, Bioniq shows strong growth through global expansion, lab integrations, and U.S./Middle East scaling.[1][4]
Bioniq was founded in 2019 in London, UK, by Vadim Fedotov, a former professional basketball player turned CEO (previously at GRPN), who experienced unexplained fatigue despite peak physical condition.[2] Doctors dismissed his symptoms, prompting Fedotov to explore Switzerland's personalized micronutrient approach, which resolved his issues and inspired the company.[2] He built it around a massive proprietary database of blood test data—now over 6 million data points from global customers—paired with a patent-pending AI algorithm.[1][4] Co-founder James Hardy, CFO with 20 years in retail, fintech, and eCommerce as a Chartered Accountant, handles finances, investor relations, market expansion, and fundraising.[2] Early traction came from partnerships with institutions like Lanserhof and King's College Hospital, acquisitions like VAHA.com and Loewi, and serving 100,000+ users.[1][2]
Bioniq rides the personalized nutrition and AI-health trend, fueled by rising demand for precision wellness amid biomarker testing accessibility and consumer skepticism of mass-market vitamins.[1][4] Timing aligns with post-pandemic health optimization booms, longevity tech advances, and AI's role in biotech—its database and algorithm set industry standards for data-driven supplementation.[1] Market forces like global wellness spending (projected trillions) and regulatory nods (SwissMedic, FDA) favor it, while partnerships with elite institutions amplify credibility.[2][4] Bioniq influences the ecosystem by normalizing blood-based personalization, inspiring competitors, and expanding via acquisitions/investors, pushing "one-size-fits-all" toward obsolescence.[1][2]
Bioniq's $15M Series B at $75M valuation positions it for aggressive growth: U.S./Middle East expansion, global lab networks, HR scaling, and institutional platforms will accelerate user acquisition beyond 100,000.[1] Trends like AI-biomarker integration, wearable health data, and elite athlete adoption (e.g., Ronaldo) will shape its path, potentially dominating personalized supps as databases grow. Its influence may evolve into a full health ecosystem—merging supps with diagnostics/apps—cementing it as the leader in making advanced nutrition accessible, just as Fedotov's personal quest sparked a global standard.[1][2][4]
Bioniq has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $15.0M Series B | HV Capital, Norrsken VC, Picus Capital |
